Literature DB >> 23834832

Effect of surface chemistry of porous silicon microparticles on glucagon-like peptide-1 (GLP-1) loading, release and biological activity.

Anne Huotari1, Wujun Xu, Juha Mönkäre, Miia Kovalainen, Karl-Heinz Herzig, Vesa-Pekka Lehto, Kristiina Järvinen.   

Abstract

Recently, mesoporous silicon (PSi) microparticles have been shown to extend the duration of action of peptides, reducing the need for frequent injections. Glucagon-like peptide 1 (GLP-1) is a potential novel treatment for type 2 diabetes. The aim of this study was to evaluate whether GLP-1 loading into PSi microparticles reduce blood glucose levels over an extended period. GLP-1 (pI 5.4) was loaded and released from the negatively charged thermally oxidized (TOPSi, pI 1.8) and thermally carbonized (TCPSi, pI 2.6) PSi microparticles and from the novel positively charged amine modified microparticles, designated as TOPSi-NH2-D (pI 8.8) and TCPSi-NH2-D (pI 8.8), respectively. The adsorption of GLP-1 onto the PSi microparticles could be increased 3-4-fold by changing the PSi surface charge from negative to positive, indicating that the positive surface charge of PSi promoted an electrostatic interaction between the negatively charged peptide. All the GLP-1 loaded PSi microparticles lowered the blood glucose levels after a single s.c. injection but surprisingly, TOPSi-NH2-D and TCPSi-NH2-D were not able to prolong the effect when compared to TOPSi, TCPSi or GLP-1 solution. However, TOPSi-NH2-D and TCPSi-NH2-D microparticles were able to carry improved payloads of active GLP-1 encouraging continuing further attempts to achieve sustained release.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Blood glucose levels; GLP-1; In vivo; Mesoporous silicon; Peptide delivery

Mesh:

Substances:

Year:  2013        PMID: 23834832     DOI: 10.1016/j.ijpharm.2013.06.063

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  4 in total

Review 1.  Factors affecting the physical stability (aggregation) of peptide therapeutics.

Authors:  Karolina L Zapadka; Frederik J Becher; A L Gomes Dos Santos; Sophie E Jackson
Journal:  Interface Focus       Date:  2017-10-20       Impact factor: 3.906

Review 2.  Battle of GLP-1 delivery technologies.

Authors:  Minzhi Yu; Mason M Benjamin; Santhanakrishnan Srinivasan; Emily E Morin; Ekaterina I Shishatskaya; Steven P Schwendeman; Anna Schwendeman
Journal:  Adv Drug Deliv Rev       Date:  2018-07-21       Impact factor: 15.470

3.  In vivo dual-delivery of glucagon like peptide-1 (GLP-1) and dipeptidyl peptidase-4 (DPP4) inhibitor through composites prepared by microfluidics for diabetes therapy.

Authors:  F Araújo; N Shrestha; M J Gomes; B Herranz-Blanco; D Liu; J J Hirvonen; P L Granja; H A Santos; B Sarmento
Journal:  Nanoscale       Date:  2016-05-19       Impact factor: 7.790

4.  Mesoporous Silicon Particles Favor the Induction of Long-Lived Humoral Responses in Mice to a Peptide-Based Vaccine.

Authors:  Gabriela Navarro-Tovar; Denisse Rocha-García; Alejandra Wong-Arce; Gabriela Palestino; Sergio Rosales-Mendoza
Journal:  Materials (Basel)       Date:  2018-06-26       Impact factor: 3.623

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.